MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer

Huaqi Wang; Li Wang; Guojun Zhang; Chunya Lu; Heying Chu; Rui Yang; Guoqiang Zhao

doi:10.18632/oncotarget.23483

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer

Huaqi Wang, Li Wang, Guojun Zhang _, Chunya Lu, Heying Chu, Rui Yang and Guoqiang Zhao

PDF | HTML | How to cite

Oncotarget. 2018; 9:7501-7512. https://doi.org/10.18632/oncotarget.23483

Metrics: PDF 1891 views | HTML 3114 views | ?

Abstract

Huaqi Wang1, Li Wang2, Guojun Zhang1, Chunya Lu1, Heying Chu1, Rui Yang1 and Guoqiang Zhao2

1Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China

2School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, P.R. China

Correspondence to:

Guojun Zhang, email: [email protected]

Guoqiang Zhao, email: [email protected]

Keywords: MALAT1; cisplatin; resistance; miR-101-3p; myeloid cell leukemia 1

Received: September 27, 2017 Accepted: November 14, 2017 Published: December 14, 2017

ABSTRACT

In this study, we investigated the mechanism by which lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) mediates cisplatin resistance in lung cancer. Lung cancer patients with high MALAT1 levels were associated with cisplatin resistance and low overall survival. Moreover, cisplatin-resistant A549/DDP cells showed higher MALAT1 expression than cisplatin-sensitive lung cancer cells (A549, H460, H1299 and SPC-A1). Dual luciferase reporter and RNA immunoprecipitation assays showed direct binding of miR-101-3p to MALAT1. MALAT1 knockdown in lung cancer cells resulted in miR-101-3p upregulation and increased cisplatin sensitivity. In addition, miR-101-3p decreased myeloid cell leukemia 1 (MCL1) expression by binding to the 3’-untranslated region (3’-UTR) of its mRNA. These results demonstrate that MALAT1/miR-101-3p/MCL1 signaling underlies cisplatin resistance in lung cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23483

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer

Abstract